Assessment of Antiradiation Drug Effectiveness to Fission Neutron Irradiation.
Annual rept. 1 Sep 82-30 Sep 83,
LOUISVILLE UNIV KY SCHOOL OF MEDICINE
Pagination or Media Count:
This report details scientific results of contracted research testing the ability of newly synthesized anti-radiation drugs to protect critical normal tissues from the adverse effects of fission neutron irradiation. Fission neutrons were obtained at the Health Physics Research Reactor HPRR at Oak Ridge National Laboratory, Oak Ridge, TN. The neutron beam had an average energy of 0.9 MeV and a dose-rate of about 55 Rads per minute. C57B16J male mice were used throughout this study. They were irradiated at two meters from the unshielded reactor core with whole body doses which varied from 0 to 600 Rads. The organ systems studied were the hematopoietic and gastrointestinal stem cell populations. The protectors examined in this study were phosphorothioates which have the greatest chance of improving survival after exposure to radiations which would be experienced in atomic weapon detonation. The drugs covered in this report are WR-347, WR-1065, WR-2529, WR-2721, WR-3689, WR-44923, WR-109342, WR-151327 and WR-168643. They were injected intraperitoneally at a dose equivalent to the one-third the toxic LD50, 30 minutes prior to irradiation. The results indicate that these agents vary considerably in their ability to protect normal tissues from the adverse effects of neutron irradiation. The study did, however, identify several agents which were surprising in their ability to protect against this high LET radiation.